Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

hVIVO Canary Wharf move to deliver material increase in capacity - Proactive Research Analyst

hVIVO PLC

Proactive research analyst Daniel Appiah speaks to Thomas Warner at the London studio about his latest report into specialist contract research organisation hVIVO. hVIVO is expanding its presence by establishing a cutting-edge facility at the Canary Wharf Life Sciences Hub in London. The expansion, primarily funded by its clients, will feature state-of-the-art amenities, including quarantine rooms, laboratories, outpatient facilities, and corporate offices all under one roof. Notably, the new site will initially offer 50 quarantine beds, with plans to expand to 70, significantly surpassing the current Whitechapel and Queen Mary facilities, which can accommodate only 43. The move enables hVIVO to conduct simultaneous challenge trials for various clients, enhancing efficiency and increasing revenue. hVIVO's H1 results showcased a remarkable 52% YoY revenue increase to approximately £27.3 million, driven by the growth of their challenge trial order book. With a strong cash position and a prepayment model, the company appears set to meet its 2023 revenue guidance of £53 million with an EBITDA between 15% and 90%. For more details, you can read Daniel's comprehensive report by following the link in the corner. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 05, 2023 08:42 AM Eastern Daylight Time

Video

Tissue Regenix Group says "disciplined approach" paying off at half-year stage

Tissue Regenix Group PLC

Tissue Regenix Group PLC (AIM:TRX) chief executive Danny Lee and chief financial officer David Cocke speak to Thomas Warner from Proactive London after the regenerative medicine company released its interim results for the first six months of 2023. Cocke reports that the company reported a remarkable 19% growth, marking the sixth consecutive period of growth since the pandemic's onset. Their BioRinse and T-cell segments demonstrated substantial growth, with the former up by 20% and the latter by 29%. Gross profit increased to 49%, owing to efficiency gains from their Phase One expansion. He suggests that the company's growth strategy, driven by a "disciplined approach" to supply, sales revenue, sustainability, and scale, has been fundamental to their success. Lee also discusses the launch of a new product under the BioRinse brand, focused on producing safe, sterile tissue for sports medicine applications in the lucrative US market, estimated at approximately $300 million. The new product will primarily be used for tendon and ligament repairs in joints like the knee, ankle and elbow. Looking ahead, the company remains committed to continued growth, both in their core business and expansion into new markets, such as the United States. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 05, 2023 08:37 AM Eastern Daylight Time

Video

The Cultivated B and denovoMATRIX Partner to Bring Cultivated Meat to Commercial-Scale Production Volumes

The Cultivated B

The Cultivated B (TCB) and denovoMATRIX have entered into a collaborative partnership to conduct a feasibility study with implications that enable the scalable, economically viable commercial production of cultivated meats. denovoMATRIX will contribute its microcarrier technology to test the proliferation of suspended cells in TCB’s bioreactors and cell mediums, and its coating technology for functionalizing scaffolding, which enables a structured final cultivated meat product. Cells, by nature, grow by adhering to a surface, inherently limiting cell growth to the surface area of the culture vessel. Microcarriers add surface area to the cell culture while simultaneously ensuring that every cell is sufficiently nurtured to further proliferate while they comfortably float freely. Microcarriers act as an adherence mechanism for cells, contributing to rapid cell doubling and overcoming growth limits. Use of microcarriers will allow industrial-scale cell mass production and establishes a controllable, consistent as well as repeatable pilot-phase process for manufacturing cell mass. This development would set a standard for the industry, enabling traditional meat companies to create and scale their own cultivated meat programs internally. "Together with denovoMATRIX, we're poised to bring our shared vision of a more sustainable, future-forward biotech sector to life," said Dr. Hamid Noori, CEO of The Cultivated B. "This collaboration not only signifies a step forward in cell line technology but also reflects our mutual dedication to progressive innovation in the cultivated meat sector." The collaboration leverages the exclusive and shared technical competencies of the two innovative German B2B technology providers to perform an in-depth analysis of the viability and potential benefits of this integrated system. This synergy will enable an end-to-end approach for the alternative protein sector. denovoMATRIX is contributing its biomaterials, as well as cell biology and development expertise, which has the potential to unlock cell growth/manufacturing opportunities for TCB's cell lines and bioreactor setups. Once the feasibility study concludes and demonstrates productive outcomes, TCB intends to integrate denovoMATRIX technology into its product offerings, marking a major stride in cellular agriculture innovation. Dr. Dejan Hušman, CEO of denovoMATRIX commented, "Our alliance with The Cultivated B is a commitment to enabling existing as well as new players in the cultivated meat space. The outcome which we strive for is a turnkey solution for customers, composed of the expertise and technologies of our two companies." The potential impact of this partnership extends beyond the commercial cultivated meat sector. With the anticipated success of the pilot-phase process, it could be adopted by academic institutions researching cultivated meat, democratizing the initiation of pilot-scale cell manufacturing. About The Cultivated B (TCB) The Cultivated B’s multinational team of scientists develops and applies breakthrough technologies in cellular agriculture, precision fermentation and advanced bioreactor technology to enable scalable commercialization of the cellular-agriculture industry. TCB serves startups, corporations and academic research institutions within the food, pharma, cosmetics and personal care industries. With its pioneering engineering and production capabilities, TCB enables other companies to produce alternative proteins, such as cultivated meat, at industrial scale. The company’s fundamental commitment to minimizing the natural resources used paves the way toward a sustainable future, locally, regionally and globally. TCB’s research and development team is based in Germany, with manufacturing and an innovation hub based in Canada’s Toronto region. For more information, visit https://www.thecultivatedb.com and follow the company on LinkedIn. About denovoMATRIX denovoMATRIX serves customers in cell therapy, cultivated meat and pharmaceutical research with tools for supporting cell isolation, manufacturing, and differentiation. Our offering is focused in three areas, including tailored biomaterials based on our proprietary platform, stem cell biology & characterization services, and finally high potency cell lines. For more information, visit: https://www.denovomatrix.com/ Contact Details The Cultivated B Jenna Beaucage +1 508-340-6851 tcb@rainerco.com Company Website https://www.thecultivatedb.com

September 05, 2023 08:04 AM Eastern Daylight Time

Image

News Release

Willow Bioscience files patent to help reduce costs of corticosteroids

Willow Biosciences Inc.

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a groundbreaking development in the pharmaceutical industry. Savile shared the company's achievement in creating a cost-effective process for producing corticosteroids using their innovative BioOxi platform. This novel approach to efficient bio-hydroxylation has the potential to revolutionize corticosteroid manufacturing. Corticosteroids are widely used for their anti-inflammatory and immunosuppressant properties, making them essential drugs in medical practice. With the corticosteroid market projected to grow to $5.93 billion by 2026, ensuring a stable supply chain is crucial. However, a significant portion of corticosteroid production occurs outside the United States, leading to potential supply chain vulnerabilities and shortages for drug manufacturers. Savile explained that Willow Bioscience's BioOxi process represents a significant advancement by substantially reducing the production costs of corticosteroids. This breakthrough is anticipated to make domestic manufacturing more competitive, encouraging the onshoring of corticosteroid production and reducing supply chain risks. If granted, the patent protection for this process could offer a remarkable competitive advantage to pharmaceutical manufacturing partners. The development of a cost-effective corticosteroid manufacturing process highlights Willow Bioscience's commitment to innovation and addressing critical challenges in the pharmaceutical industry. By leveraging its BioOxi platform, the company is not only transforming manufacturing practices but also contributing to the security and availability of essential medications for patients worldwide. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 04, 2023 01:31 PM Eastern Daylight Time

Video

Oxford Cannabinoid Technologies in a "comfortable position" ahead of Phase 1 results release

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief executive Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after publishing final results for the year to 30 April 2023. She gives her take on the highlights from the year, which included the completion of preclinical work on two lead programs and the filing of the clinical trial application for lead compound 461201. She also expresses pride in being recognised as a top workplace in the Sunday Times' Best Places to Work Awards, and acknowledges the guidance of esteemed experts on their Scientific Advisory Board. Sowemimo-Coker confirms that the eagerly-awaited phase one clinical trial results for Oxford Cannabinoid Technologies' first program are on track for release during the current quarter. In terms of funding, she reassured investors that the company's prudent financial management has ensured full funding through to April 2024, supporting ongoing program development and potential phase two advancement. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 01, 2023 08:11 AM Eastern Daylight Time

Video

Faron Pharmaceuticals kicks off second half with FDA announcement

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) CEO Markku Jalkanen and CFO James O'Brien speak to Thomas Warner from Proactive after the clinical stage biopharmaceutical company revealed its been granted orphan drug designation by the US Food and Drug Administration (FDA) for its bexmarilimab asset to treat acute myeloid leukaemia. The news was published alongside Faron's first-half results. Jalkanen gives an overview of how the company's BEXMAB study is progressing so far, highlighting the accelerated achievement of complete remission among patients who had limited options. Jalkanen stated that the treatment's dual action mechanism, stimulating the immune system and targeting cancer cells, was ideally designed for this context. He goes on to address the granting of orphan status from the FDA, before CFO James O'Brien speaks specifically about the company's finances. He says Faron has raised over €18 million this year, positioning itself strongly with cash reserves exceeding €12.8 million for future operations. He suggests that Faron is currently funded through to the end of the end of this calendar year with several options for extending the cash runway. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 01, 2023 08:03 AM Eastern Daylight Time

Video

News Release

BioHarvest Sciences latest financial numbers shows continued growth for flagship product VINIA

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share significant achievements from the company's second-quarter results. Sobel highlighted key performance indicators that demonstrate BioHarvest's robust growth and strategic advancements. A standout achievement was the remarkable growth in revenue generated by the company's flagship product, VINIA. BioHarvest Sciences achieved $2.75 million in revenue from VINIA in 2Q 2023, marking an impressive 228% increase compared to the same quarter of the previous year. This revenue figure also represents a 27% growth compared to the previous quarter, Q1 2023. The strong revenue growth showcases the increasing demand and market acceptance of the VINIA product. Sobel emphasized the significant improvement in gross product margins for the quarter. The gross product margin increased to 40%, a substantial jump from 12% in Q2 2022. This improvement is attributed to scaling production and achieving operational efficiencies. BioHarvest Sciences anticipates that these margins will continue to rise as production continues to expand. The company's recurring revenue model was highlighted as a key driver of its success. Sobel discussed the growth in both new customers and total subscribers, demonstrating the power of this model to accelerate revenue growth and contribute to achieving profitability. Notably, the total active VINIA subscribers increased by a remarkable 620% compared to Q2 2022, showcasing the growing interest and adoption of the product. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

August 31, 2023 01:38 PM Eastern Daylight Time

Video

News Release

Avricore Health CEO feels company is set up for success with new partnerships and emerging markets

Avricore Health

Avricore Health CEO Hector Bremner discussed the company's significant growth, partnerships, and expansion into new markets during an interview with Steve Darling from Proactive. Bremner shared how these developments position Avricore Health for future success, with a strong focus on the company's flagship product, HealthTab. Bremner emphasized that the core of Avricore Health's operations centers around HealthTab, an innovative health monitoring solution. The company is working on expanding the reach of HealthTab by partnering with more pharmacies not only across Canada but also on a global scale. This expansion strategy aims to bring HealthTab's benefits to a wider audience and increase the company's market presence. Regarding financial performance, Bremner highlighted the impressive growth achieved by Avricore Health. Revenues for the first half of 2023 reached $1,177,290, representing a remarkable 437% increase compared to the same period in the previous year. This growth was attributed to the deployment of more HealthTab systems and increased tests sold. Additionally, the company's gross profit surged by 511% to $440,152, with a gross margin of 37.39% — outperforming the company's target margin of 30%. This performance underscores the solid fundamentals of the company and its ability to increase scale while simultaneously improving profitability. Avricore Health's success story also includes its recent selection by a collaborative effort involving the renowned Barts Heart Centre and the national cardiovascular charity HEART UK. The company was chosen to assess the feasibility of integrating cholesterol testing into community pharmacies in the UK. This initiative aims to complement opportunistic blood pressure checks, assess cardiovascular risk, and expand clinical services offered to patients. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 31, 2023 01:28 PM Eastern Daylight Time

Video

POLARISqb and Syntekabio sign MOU for Collaborative AI and Quantum-powered Drug Development Service

Syntekabio, Inc.

POLARIS qb, the first company in the world to develop a drug discovery engine that utilizes the optimization power of quantum computing, announced that it has signed an MOU with Syntekabio (KOSDAQ: 226330), an Artificial Intelligence (AI) based drug development company. The partnership, which will combine the companies’ vanguard drug research platforms, will provide a collaborative drug development service as well as develop new molecular leads. Through this business agreement, the two companies will discover active compounds with their respective AI and Quantum Computing platforms. Using these technologies, they will search for candidates with high druggability potential and offer these candidates to customers seeking novel molecular leads. POLARIS qb is a quantum computing-based drug development company in Durham, North Carolina. As a leader in applying quantum computing in the world of drug discovery, the company has shortened the timelines for finding novel drug-like leads by orders of magnitude. In addition, POLARIS qb has recently developed Quantum-Aided Drug Design (QuADD), a platform for generating new drug candidates using quantum annealing from exceptionally large molecular libraries. Using the increased optimization power of today’s quantum computers, this process can be accomplished in days rather than months. In this partnership they will leverage this optimization potential of quantum annealing computers, allowing the company to search a chemical space of 10 30 potential molecules, a space many times larger than other computational chemistry platforms. Based on its own cloud supercomputing infrastructure, Syntekabio prepares big genomic data and AI drug platform services for implementation throughout the entire life cycle of novel drug development processes. Their platform includes services from the discovery of active compounds to the development of pre-clinical stage drug candidates (called DDC Service: DeepMatcher® Drug Candidate Service), as well as genomic biomarker discovery and detection services. Syntekabio plans to diversify lead candidates by applying POLARIS qb 's QuADD platform in the lead generation stage of DDC service. In addition, the two companies plan to jointly market their offering to global markets with specific emphasis on the US, Europe, and Asia. Combining the advantages of POLARIS qb 's quantum-based system and Syntekabio's AI discovery platform enhances precision medicine. This partnership seeks to help develop treatments to address various conditions and diseases that affect millions around the globe. Shahar Keinan, co-founder and CEO of POLARIS qb, said, “QuADD is a quantum computing-based platform that is relevant to the pharma global market, representing a commercialized quantum product in the field of new drug design.” She added, "We expect to be able to find lead candidates quickly and efficiently in this partnership by providing new drug development services using Syntekabio's cloud supercomputer infrastructure and genome-based AI platform." Jongsun Jung, CEO of Syntekabio, said, "We are delighted that Syntekabio's DeepMatcher® and POLARIS qb 's QuADD can cooperate to provide a drug candidate discovery service. It will be of great help in expanding global business opportunities as we work together.” For more information about POLARIS qb and its offering, please visit: http://www.polarisqb.com/. For more information about Syntekabio and its offering, please visit: https://cloud.syntekabio. com/. Contact Details Ellie Woo, BD Director +1 212-371-2544 ellie.woo@syntekabio.com Company Website https://cloud.syntekabio.com/

August 31, 2023 09:00 AM Eastern Daylight Time

Image

1 ... 79 80 81 82 83 ... 250